Search Results
Feb 10, 2026, 18:15 ET Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR
More news about: Ascletis Pharma Inc.
Feb 10, 2026, 16:06 ET Novo Nordisk submete Wegovy® comprimidos (semaglutida oral 25 mg), para o tratamento da obesidade, à aprovação regulatória da ANVISA
convenientes para a obesidade, uma doença que exige abordagens individualizadas e de longo prazo. Como já temos o Rybelsus®, o único comprimido de GLP-1, no mercado para o tratamento do diabetes, sabemos o quão importante é para alguns pacientes ter uma opção oral disponível para tratar doenças crônicas.",
More news about: Novo Nordisk
Feb 10, 2026, 11:17 ET Nation's Largest Thyroid Cancer Center Publishes White Paper Finding No Convincing Evidence That GLP-1 Medications Cause Common Thyroid Cancers
studies and meta-analyses have not found increased thyroid cancer rates among GLP-1 users. Some studies showing possible "associations" may be explained by detection bias. Patients on GLP-1 therapy often have more medical visits, imaging, and specialist care, which can increase
More news about: Clayman Thyroid Center
Feb 10, 2026, 10:54 ET Meijer anuncia un nuevo acceso asequible a medicamentos GLP-1
enorgullece de ofrecer mayor acceso a los medicamentos GLP-1 a un precio que permite a las personas hacerse cargo de su salud y nuestro equipo cuenta con los conocimientos que nuestros clientes necesitan a la hora de seleccionar los tratamientos con GLP-1".El compromiso de Meijer va más allá de la medicación.
More news about: Meijer
Feb 10, 2026, 09:01 ET Meijer Announces New Affordable Access to GLP-1 Medications
offer greater access to GLP-1 medications at a price that allows individuals to take charge of their health, and our team is equipped with the knowledge our customers need when selecting GLP-1 treatments."Meijer's commitment goes beyond
More news about: Meijer
Feb 10, 2026, 08:30 ET Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
a potential gamechanger in the $200 billion obesity market, offering a differentiated mechanism that could address limitations of current GLP-1 agonists like gastrointestinal side effects and muscle loss. With obesity affecting over 1 billion people globally and MASLD impacting up to 30%
More news about: Hoth Therapeutics, Inc.
Feb 10, 2026, 05:36 ET Sunlight.com Survey: GLP-1 Weight Loss Is Changing Dating and Relationships
GLP-1 medications is reshaping romantic relationships, boosting confidence, dating success, and intimacy for many users while creating strain for a smaller group. The January 2026 survey of 1,000 GLP-1 users who lost more than
More news about: Sunlight
Feb 09, 2026, 18:39 ET CEIPA dan Toyota Group Berkolaborasi dengan Gig Life Pro untuk Menggelar "Tsudoi '26 Japanese Industry Mixer - Indonesia Edition"
https://www.giglifepro.com/members/events/explore/glp-x-ceipa-indonesia-mixer-music-way-projectTentang CEIPA & TOYOTA GROUP MUSIC WAY PROJECTSeiring minat global yang semakin
More news about: Gig Life Pro
Feb 09, 2026, 06:30 ET BD Reports First Quarter Fiscal 2026 Financial Results
Syringe production at its Columbus, Nebraska site. Investment will expand production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.Announced expanded partnership with Ypsomed to address the rapidly growing
More news about: BD (Becton, Dickinson and Company)
Feb 09, 2026, 01:05 ET Google Reclaims No. 1 Spot at the 2026 Kellogg School Super Bowl Advertising Review
to care. Weight-loss medications were especially prominent, with Novo Nordisk (Wegovy), Ro, and Eli Lilly (Zepbound) all spotlighting their GLP-1 offerings. Together, these spots signaled a broader evolution in the advertising mix, with seemingly fewer traditional snack and candy brands taking
More news about: Kellogg School of Management
Feb 06, 2026, 09:08 ET Novo Nordisk takes the field at the big game, putting Wegovy® pill in consumers' hands
Novo Nordisk's first big game spot introduces America to the FDA-approved Wegovy® pill — the first and only GLP-1 pill for weight loss — empowering people with a new way to manage their weight"A New Way to Wegovy®"
More news about: NOVO NORDISK INC.
Feb 06, 2026, 06:02 ET 13 Top Press Releases from January
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America"This moment is about changing what's possible in weight management,
More news about: PR Newswire
Feb 05, 2026, 16:47 ET What Is Fibermaxxing? Life Time Experts Share Simple, Safe Ways to Add More Fiber Daily
Viral social media trend spotlights America's fiber gap, fiber's role in long-term health, and its importance for people using GLP-1 medicationsCHANHASSEN, Minn., Feb. 5, 2026 /PRNewswire/ --
More news about: Life Time, Inc.
Feb 05, 2026, 06:30 ET From Lifestyle Issue to Economic Priority: How Metabolic Health is Reshaping Policy and Healthcare Planning in the GCC
research-led report by FINN Partners, a full-service global marketing and communications consultancy, identifies metabolic health innovation, including GLP-1 therapies, as a key force accelerating this transformation. The report,
More news about: FINN Partners
Feb 04, 2026, 19:29 ET GLP China Holdings Limited TENDER OFFER TO PURCHASE FOR CASH ANY AND ALL OF ITS U.S.$700,000,000 2.95 PER CENT. NOTES DUE 2026
2025) by GLP (the "New GLP Notes"), which was initially announced by GLP, on 5 February 2026 (the "New Financing Condition"). Nothing in the Tender Offer Memorandum or this announcement constitutes an offer to sell or the solicitation of an offer to buy the New GLP Notes. Subject
More news about: GLP China Holdings Limited
Feb 04, 2026, 16:05 ET Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
Feb 04, 2026, 09:00 ET LifeNet Health Achieves ISO 9001:2015 Certification, Advancing High-Quality Research That Expands Access to Healthcare Innovation
development testing in materials science and pharmaceutical safety. The laboratory's operations are also aligned with 21 CFR Part 58 Good Laboratory Practice (GLP) requirements for non-clinical studies, supporting data integrity, traceability, and audit readiness.ISO 9001:2015 is an internationally recognized
More news about: LifeNet Health
Feb 04, 2026, 08:00 ET MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Feb 04, 2026, 06:45 ET Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from injectable incretins to oral GLP-1 therapy, and retatrutide for people with obesity and knee osteoarthritis.Announced an agreement with the U.S. government to expand
More news about: Eli Lilly and Company
Feb 03, 2026, 17:31 ET Insulin Resistance Market Expected to Witness Strong Growth During the Forecast Period (2026-2036) | DelveInsight
markers that capture subclinical insulin resistance.Advancements in Therapeutic Options: Innovative drug classes, such as GLP-1 receptor agonists and SGLT2 inhibitors, that improve insulin sensitivity and support weight management are being widely adopted, expanding treatment
More news about: DelveInsight Business Research, LLP
Feb 03, 2026, 16:01 ET AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
cafraglutide, AMG 133)MariTide is a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR).MARITIME-1, a Phase 3 study of MariTide for
More news about: Amgen
Feb 03, 2026, 10:46 ET Prefilled Auto Injectors Market Surges to USD 11.2 Billion by 2033, Propelled by 8.4% CAGR - Verified Market Reports®
strong penetration in this segment.Diabetes remains a foundational application area, particularly as next-generation insulin analogs and GLP-1 receptor agonists gain market share. While insulin pens are well established, auto injectors are increasingly used for adjunct therapies and fixed-dose
More news about: Verified Market Reports
Feb 03, 2026, 08:00 ET Dash Bio Expands Operations with 24,000 Square Foot GLP-Compliant Facility in Waltham, MA. February 3, 2026
bioanalysis CRO redefining speed in drug development, announced it has moved into a new 24,000 square foot facility in Waltham, Massachusetts. This GLP-compliant lab represents a over 5-fold expansion, and is already operational and accepting projects with no delay.
More news about: Dash Bio
Feb 03, 2026, 08:00 ET ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally PNS
More news about: ZipBio
Feb 03, 2026, 06:30 ET Deep EigenMatics Ranks #1 Globally in AI Drug Discovery, Outpacing All of Big Pharma in 2025 Patent Output
models of legacy firms.Strategic Target Announcement: Oral GLP-1Building on this momentum, Deep EigenMatics is officially announcing the selection of the Oral GLP-1 category (Glucagon-like peptide-1 receptor agonists) as its lead therapeutic
More news about: Deep EigenMatics